Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Key Inclusion Criteria:

1. Currently participating in a BeiGene- or BeOne-sponsored eligible parent study

2. Fulfills treatment criteria specified in the parent study protocol

3. In the opinion of the investigator, the participant will continue to benefit fromand tolerate any of the parent study treatments.

4. The first dose of study treatment in the LTE study will be received within thetreatment interruption period allowed by the parent study:

5. "Treatment interruption" is an unplanned pause in study treatment (eg, due toadverse event). Restarting study treatment beyond the interruption periodallowed by the parent study will be determined by the investigator and thesponsor.

Key Exclusion Criteria:

1. Permanently discontinued from all investigational drugs in the parent study due tounacceptable toxicity, noncompliance with study procedures, or withdrawal of consent

2. Have uncontrolled active systemic infection or recent infection requiring parenteralantimicrobial therapy prior to the start of the extension study

3. Have a medical condition or organ system dysfunction that in the investigator'sopinion, could compromise the participant's safety, interfere with the absorption ormetabolism of investigational drugs, or put the study outcomes at undue risk

4. Underwent treatment with any systemic anticancer treatment (other than treatmentpermitted in the parent study) during the time between the last treatment in theparent study and the first dose of study treatment in the LTE study

5. Pregnant or lactating women

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.